Aniracetam

Chemical identity

Aniracetam is 1-(4-methoxybenzoyl)-2-pyrrolidinone — a piracetam core acylated with an anisoyl group. That aromatic substituent transforms the compound's physical properties: where piracetam and oxiracetam are water-soluble, aniracetam is lipophilic and practically insoluble in water.

The lipophilicity is the defining practical feature of this molecule. It governs solubility, formulation, absorption and, in the published work, the compound's rapid and extensive first-pass metabolism.

Mechanism in research models

Aniracetam is the racetam with the clearest mechanistic characterisation. It is a positive allosteric modulator of AMPA receptors, acting by slowing receptor desensitisation rather than by increasing agonist affinity — extending the current through the channel in response to a given glutamate pulse.

This action places it in the ampakine class alongside the CX-series compounds, and it has been used as a reference modulator in AMPA receptor electrophysiology. The effect is measurable directly in patch-clamp preparations, which is why this mechanism is better established than anything in the wider racetam literature.

Additional reported effects on cholinergic, dopaminergic and serotonergic transmission are largely attributed to downstream consequences of AMPA modulation rather than to direct action at those systems.

What the literature establishes

The AMPA electrophysiology is solid, replicated and mechanistically specific. If a study needs a reference AMPA desensitisation modulator, this is a defensible choice.

The behavioural and clinical literature is weaker. Studies in dementia and post-stroke cognition from the 1990s report modest effects, but the pharmacokinetics complicate interpretation: aniracetam undergoes near-complete first-pass metabolism, and the principal circulating species are its metabolites — chiefly N-anisoyl-GABA — rather than the parent compound.

That metabolic profile means in-vivo results may reflect metabolite activity, while in-vitro results reflect the parent. The two literatures are not describing the same chemical entity, and conflating them is the most common error in secondary sources on this compound.

Handling, storage and solubility

Typically held sealed at room temperature or below, protected from light and moisture, and stable as a dry solid; the validated condition and the physical form are the ones stated on the lot documentation.

Practically insoluble in water; soluble in ethanol, DMSO and lipid vehicles. In-vitro work requires an organic stock with vehicle-matched controls; in-vivo work generally requires a lipid or suspension formulation, and the vehicle choice materially affects the exposure achieved.

Aqueous suspensions settle. Where a suspension is used, agitation immediately before each withdrawal is the difference between a reproducible dose and an unknown one.

Analytical documentation

Require HPLC purity, NMR and mass confirmation. The methoxybenzoyl group gives strong UV absorbance, so purity by HPLC-UV is straightforward for this compound and there is no reason to accept a vague figure.

Where pharmacokinetic work is planned, establish an assay for N-anisoyl-GABA alongside the parent. Measuring only aniracetam in plasma will substantially understate exposure.

References and authoritative sources

Chemical identity, regulatory status and anti-doping classification should be confirmed against primary sources rather than against this page. The records below are the ones to check first.

1. PubChem compound record (US National Library of Medicine)
2. PubMed indexed literature
3. ClinicalTrials.gov registered studies

These are database and regulatory sources. Citations to specific primary papers are being added to this page as part of ongoing scientific review; until they appear, treat the mechanism and literature sections above as a summary to verify rather than a citation of record.